GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algorae Pharmaceuticals Ltd (ASX:1AI) » Definitions » EBITDA Margin %

Algorae Pharmaceuticals (ASX:1AI) EBITDA Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Algorae Pharmaceuticals EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Algorae Pharmaceuticals's EBITDA for the six months ended in Dec. 2023 was A$-1.50 Mil. Algorae Pharmaceuticals's Revenue for the six months ended in Dec. 2023 was A$0.00 Mil. Therefore, Algorae Pharmaceuticals's EBITDA margin for the quarter that ended in Dec. 2023 was 0.00%.


Algorae Pharmaceuticals EBITDA Margin % Historical Data

The historical data trend for Algorae Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algorae Pharmaceuticals EBITDA Margin % Chart

Algorae Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -41,100.00 -104,866.67 - - -

Algorae Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Algorae Pharmaceuticals's EBITDA Margin %

For the Biotechnology subindustry, Algorae Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Algorae Pharmaceuticals's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algorae Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Algorae Pharmaceuticals's EBITDA Margin % falls into.



Algorae Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Algorae Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Jun. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2023 )/Revenue (A: Jun. 2023 )
=-2.129/0
= %

Algorae Pharmaceuticals's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-1.501/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Algorae Pharmaceuticals  (ASX:1AI) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Algorae Pharmaceuticals EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Algorae Pharmaceuticals's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Algorae Pharmaceuticals (ASX:1AI) Business Description

Traded in Other Exchanges
Address
201 Sussex Street, Level 16, Tower 2, Darling Park, Sydney, NSW, AUS, 2000
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for undermet medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. Its lead products comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. It is conceptualised to be a potential treatment for dementia, including Alzheimer's disease; NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.

Algorae Pharmaceuticals (ASX:1AI) Headlines

No Headlines